Biotech firm Asylia Therapeutics raises $14.5M, names founding CEO

Houston-based biotechnology firm Asylia Therapeutics Inc. raised $14.5 million to advance its clinical trials for cancer drugs. The Series A round was led by Houston-based Sporos Bioventures, Asylia announced May 25. The company will use proceeds to bring Asylia's assets to first-in-human clinical trials for oncology. Asylia could potentially generate proof-of-concept signals for its clinical assets in treating autoimmune diseases like lupus, the firm said. "While cancer research has come a significant…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news